Clinical diagnostics
Variant interpretation for hereditary disease, oncology (solid tumours, haematology, liquid biopsy) and preconception screening. Variant classification according to ACMG guidelines, with traceable evidence and sources.
Bioinformatics · Clinical interpretation · Databases
QIAGEN Digital Insights — tools for NGS and genomics
QIAGEN Digital Insights is the QIAGEN division focused on bioinformatics and the clinical interpretation of genomic data. The portfolio covers the path from raw NGS data to a clinically actionable output. It includes tools for data analysis (CLC Workbench), variant interpretation (Franklin, QCI Interpret) and expert-curated databases (HGMD, HSMD, COSMIC). QIAGEN Digital Insights tools are used by more than 4,000 organisations worldwide.
- 4,000+ Organisations worldwide
- 575,000+ Curated mutations in HGMD
- 2.24M Somatic variants in HSMD
- 32M Genomic variants in COSMIC
About
From data to clinical decision
QIAGEN Digital Insights is the bioinformatics division of QIAGEN. It was built through successive acquisitions of CLC bio, Ingenuity and N-of-One, and in 2025 the portfolio expanded to include the Franklin platform (acquisition of Genoox). The aim is to cover the entire process from raw NGS data to clinical interpretation without having to combine tools from different vendors.
The portfolio rests on three pillars. Tools for clinical practice (Franklin, QCI Interpret) help diagnostic labs classify variants quickly and accurately and create clinical reports. Research tools (CLC Workbench, IPA) are used for NGS data analysis without coding and for data integration in translational research. Reference databases (HGMD, HSMD, COSMIC) are expert-curated resources that both of the other tool groups draw on.
Focus & applications
Where QIAGEN Digital Insights is used
Oncology and targeted therapy
Analysis of somatic variants from FFPE samples and liquid biopsy, matching with targeted therapy options, supporting material for tumour boards, HRD and MSI assessment. The clinical report for the oncologist is ready within minutes.
Hereditary disease
Analysis of germline variants from WES and WGS in rare disease diagnostics. Expert-curated HGMD content, together with insights from the expert community, helps shorten the path to diagnosis.
Translational research & drug discovery
CLC Workbench with predefined analysis workflows, IPA for pathway analysis and the HSMD and COSMIC databases are commonly used in pharmaceutical research and development.
QIAGEN Digital Insights products
Seven key tools
Franklin
Cloud-based AI platform for the analysis and interpretation of germline and somatic variants.
Product detailQCI Interpret
A solution for clinical laboratories. Supports NGS data interpretation from input FASTQ data to the final clinical report.
Product detailCLC Genomics Workbench
Bioinformatics data analysis without coding: RNA and DNA sequencing, methylation analysis, de novo genome assembly, variant calling.
Product detailIngenuity Pathway Analysis (IPA)
A platform for the analysis and biological interpretation of omics data using expert-curated knowledge of genes, pathways, regulators and molecular interactions.
Product detailHGMD Professional
Human Gene Mutation Database: an expert-curated database of germline variants associated with inherited diseases.
Product detailHSMD
Human Somatic Mutation Database: a database of 2.24 million somatic variants from real-world oncology cases.
Product detailCOSMIC
Catalogue Of Somatic Mutations In Cancer: a comprehensive database of somatic mutations in cancer, also available for commercial use.
Product detailLet's get started
Which tool fits your lab?
We'll help you choose, arrange a trial licence and organise training. We supply the QIAGEN Digital Insights portfolio in the Czech Republic and Slovakia.